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IMPORTANCE Outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain 51 
poor. Advances in next-generation sequencing provide a route to therapeutic approaches, and it 52 
is hoped that integrating DNA and RNA analysis with clinicopathologic data is a crucial step to 53 
design personalized strategies for this lethal disease.  54 
OBJECTIVES To classify PDAC according to distinct mutational processes, and explore their   55 
clinical significance. 56 
DESIGN, SETTING AND PARTICIPANTS We performed a retrospective cohort study of 57 
resected PDAC, using cases collected between 2008 and 2015 as part of the International Cancer 58 
Genome Consortium. The discovery cohort comprised 160 PDAC from 154 patients (148 59 
primary; 12 metastases) that underwent tumor enrichment prior to whole genome (WGS) and 60 
RNA sequencing. The replication cohort comprised 95 primary PDAC that underwent WGS and 61 
expression microarray on bulk biospecimens. 62 
INTERVENTIONS 144 discovery and 95 replication cohort patients underwent curative-intent 63 
surgery and standard peri-operative management. Treatment data for 24 discovery patients who 64 
received neoadjuvant, adjuvant or palliative platinum-based chemotherapy were available for 65 
analysis. 66 
MAIN OUTCOMES AND MEASURES Somatic mutations accumulate from sequence-specific 67 
processes creating signatures detectable by DNA sequencing. Using non-negative matrix 68 
factorization, we measured the contribution of each signature to carcinogenesis, and used 69 
hierarchical clustering to subtype each cohort. We examined expression of anti-tumor immunity 70 
genes across subtypes to uncover biomarkers predictive of response to systemic therapies. 71 
RESULTS Five predominant mutational subtypes were identified that clustered PDAC into four 72 
major subtypes: Age Related; Double-strand break repair (DSBR); Mismatch repair (MMR), and 73 
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one with unknown etiology (Signature 8). These were replicated and validated. Signatures were 74 
faithfully propagated from primaries to matched metastases, implying their stability during 75 
carcinogenesis. Half of the DSBR cases lacked germline or somatic events in canonical 76 
homologous recombination genes – BRCA1, BRCA2 or PALB2. DSBR and MMR subtypes were 77 
associated with increased expression of anti-tumor immunity, including activation of CD8+ T-78 
lymphocytes (GZMA and PRF1) and over-expression of regulatory molecules (CTLA-4, PD-1 79 
and IDO-1), corresponding to higher frequency of somatic mutations and tumor-specific 80 
neoantigens. 81 
CONCLUSIONS AND RELEVANCE Signature-based subtyping may guide personalized therapy 82 
of PDAC in the context of biomarker-driven prospective trials. 83 
 84 
  85 
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Pancreatic ductal adenocarcinoma (PDAC) has the lowest 5-year overall survival (OS) of any 86 
epithelial carcinoma1. Randomized trials2,3 of adjuvant4 and palliative5,6 cytotoxic 87 
chemotherapies show modest endpoint improvements with considerable attendant toxicities. 88 
Targeted agents trialed without biomarker selection, including evofosfamide, PD-L17, CTLA-48 89 
and ERBB29 inhibitors, have not improved OS, except for marginal benefit from erlotinib10-12. 90 
PDAC outcomes will improve with rational molecular subtyping and ensuing directed therapies, 91 
as with breast13 and lung14 carcinomas. The PDAC exome15-17 contains four driver genes, KRAS, 92 
TP53, CDKN2A and SMAD4, and few disturbed pathways that are not translatable into predictive 93 
subtypes. Stratification by somatic events, including MYC amplification and specific KRAS 94 
mutant codons17, is not consistently prognostic. Structural variation in 100 genomes18 identified 95 
four PDAC subtypes, with one predictive of platinum chemotherapy response, but progression-96 
free (PFS) and OS were not assessed. Finally, prognostic transcription-based subtypes have been 97 
described19 and refined20,21, but with neither relation to genomic features nor therapeutic 98 
implications. 99 
Cancer genomes accumulate mutations over cell cycles from DNA damage and repair. 100 
Analyses of these processes22,23, informative in other tumors24-26, have not been comprehensively 101 
reported in PDAC. Signatures representative of each process22 can be quantified per tumor, and 102 
the population of tumors subtyped25 by their relative contributions. Genomic and transcriptomic 103 
landscapes of anti-tumor immunity have been systemically explored in other tumor types23 and 104 
predict response to immunotherapies26,27, however, the character of immune infiltration and its 105 
association with mutational signatures has not been studied in PDAC. 106 
We integrated genome, transcriptome and clinicopathologic data from two independent 107 
datasets to define four major signature-based PDAC subtypes. These aligned with known 108 
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hereditary pancreas cancer predisposition syndromes (HPCSs)28, were propagated from primary 109 
tumors to paired metastases, and differentially expressed anti-tumor immune markers. 110 
METHODS 111 
Whole genome sequencing (WGS) variant calls, RNA sequencing and microarray expression 112 
values, clinical information and metadata for discovery and replication cohorts are available 113 
from the ICGC data portal29 (http://dcc.icgc.org). Discovery cohort samples underwent tumor 114 
enrichment prior to sequencing. All reads were processed through the same data workflows. 115 
Bioinformatics tool names and versions are provided in Supplement One. 116 
 117 
RESULTS 118 
Mutational signatures define four principal PDAC subtypes 119 
Our discovery cohort consisted of 148 primary PDAC and 12 metastases from 154 patients that 120 
underwent WGS (Figure 1a, eTable 1). For replication, 95 whole PDAC genomes from 95 121 
patients were obtained from the ICGC (eFigure 1, eTable 1). 122 
We identified 11 mutational signatures in our discovery and 12 in our replication 123 
genomes using the approach of Alexandrov et al.30, which were merged by shared etiologies into 124 
7 signatures per cohort. Hierarchical clustering by the proportion of single nucleotide variants 125 
(SNVs) attributable to each signature (eFigure 2ab) in each cohort independently confirmed four 126 
major subtypes: 1) an “Age Related” group dominated by Signatures 1 and 5, attributed to clock-127 
like mutational processes accumulated over cell divisions31; 2) a “double strand break repair, 128 
DSBR” group characterized by Signature 3, attributed to deficiencies in homologous 129 
recombination repair (HRR) of double-strand breaks; 3) a “mismatch repair, MMR” group 130 
characterized by Signatures 6, 20 and 26, attributed to defects in DNA MMR; and 4) a group 131 
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characterized by Signature 8, of unknown etiology (Figure 1a; eFigure 1). There were two minor 132 
groups in both cohorts, one dominated by Signature 17, another by APOBEC. Tumor cellularity 133 
and coverage were consistent between subtypes (eFigure 3). Subtype prevalence was equivalent 134 
between cohorts (p=0.075, chi-squared). 135 
We verified that signatures associated with their attributed etiologies. The number of 136 
SNVs in Signatures 1 and 5 correlated with patient age at diagnosis across all cases 137 
(rdiscovery=0.21, pdiscovery=0.0077; rreplication=0.23, preplication=0.03; Pearson’s correlation), while total 138 
SNVs did not (eFigure 4). 139 
Tumors dysfunctional in HRR rely on non-conservative forms of DSBR, namely single 140 
strand annealing, which creates large structural deletions32,33, and non-homologous end-joining 141 
and microhomology-mediated end joining, which create short deletions (3-20 base pairs in 142 
length). Consistent with this, DSBR cases had greater numbers of both large structural and short 143 
deletions greater than 3 base pairs relative to Age Related cases (pdiscovery<3x10-9 for each; 144 
preplication<3x10-4; Wilcoxon) (Figure 1a; eFigure 5). 145 
MMR cases had dramatically more SNVs than Age Related cases (pdiscovery=0.0007; 146 
Wilcoxon) (Figure 1a). MMR deficiency was verified by immunohistochemistry and a PCR-147 
based assay (eTable 2). Of the four MMR cases, three had germline and one had only somatic 148 
mutations in MMR genes (eTable 3). Published frequencies of MMR deficiency in PDAC vary 149 
widely17,34. Absence of MMR from the replication cohort is likely due to its smaller size. To 150 
validate MMR prevalence, we stained a tumor microarray of 370 PDAC from the European 151 
Society Group for Pancreatic Cancer (ESPAC)35-37 for four MMR proteins. Of 342 successfully 152 
stained, six were immunodeficient. Assuming discovery, replication and ESPAC cohorts to be 153 
unbiased samplings of one population, we infer MMR deficiency prevalence in PDAC to be 154 
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1.7% (0.65-2.7%), nearly equal to that of Lynch syndrome in PDAC38 (eTable 4). Somatic MMR 155 
deficiency thus contributes little to PDAC, unlike colorectal39 and endometrial40 cancers. 156 
The discovery cohort included 12 metastases – 10 Age Related, 1 DSBR and 1 MMR. 157 
Five of these were matched with three primaries and showed faithful propagation of signatures 158 
(Figure 1b), including a DSBR pair with a germline PALB2 mutation. This implies that 159 
mutational processes are established early in carcinogenesis and is important for trials where 160 
PDAC metastases are more safely biopsied. Paired primaries and metastases were obtained at 161 
autopsy from patients who received palliative chemotherapy (eTable 5). 162 
 163 
Tiers of DSBR deficiency 164 
Clinical interest in HRR deficiency is growing, with tailored treatment strategies for breast41 and 165 
ovarian42 cancer. Of 17 discovery DSBR cases, 11 are explained by bi-allelic inactivation of 166 
BRCA1, BRCA2 or PALB2. Nine had pathogenic germline mutations with somatic inactivations 167 
of the second allele, and two had bi-allelic somatic inactivations (eTable 6). The remaining six 168 
were occult, lacking germline or somatic inactivation of canonical HRR genes, referred to as 169 
“BRCAness” in the literature33. DSBR etiology in the replication cohort was similar, with two 170 
germline, two somatic and six BRCAness. We inferred DSBR prevalence in PDAC to be 10.8% 171 
(95%CI 7.0-14.7%), comprising 4.4% (1.9-7.0%) germline deficiency, 1.6% (0.04-3.2%) 172 
somatic, and 4.8% (2.2-7.5%) BRCAness. This germline frequency is nearly equal to the 173 
prevalence of germline BRCA1 or BRCA2 deficiency in PDAC43, implying PALB2 contributes 174 
minimally to PDAC predisposition. 175 
In the amalgamated discovery and replication DSBR cases, the proportion of SNVs 176 
attributed to Signature 3 was greater in germline than somatic cases, with BRCAness cases 177 
intermediate (Figure 2). The number of SNVs attributed to a mutational process likely increase 178 
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with its duration in tumorigenesis30. Thus, germline cases may become HRR deficient earlier, 179 
while somatic cases become deficient later or sub-clonally, with BRCAness an admixture of both 180 
etiologies. This may have implications for therapies targeting HRR deficiency. BRCAness cases 181 
also have relatively low numbers of SVs (Figure 2) and may alternatively harbor a mutational 182 
process distinct from classical HRR deficiency. 183 
Assuming one or few genes with “two hits” explain the 12 BRCAness cases, we 184 
agnostically compared frequencies of bi-allelic inactivation of genes in the DSBR and Age 185 
Related tumors of our amalgamated cohorts (Figure 3). We considered only primaries since 186 
metastasis-specific events were reported in PDAC44. BRCA2 was the only gene preferentially 187 
inactivated in the DSBR group (FDR 0.004%). 188 
The idiopathic Signature 8 is similar to Signature 3, with the additional feature of strand 189 
bias for C>A substitutions. The latter was reported in PDAC exomes17 and attributed to smoking, 190 
a PDAC risk factor45, although our data do not support this epidemiologic association (eFigure 191 
6). Signature 8 is also found in breast cancer30,46, suggested as due to either past activity of 192 
transcription-coupled nucleotide excision repair, or to HRR deficiency. Comparison of 193 
frequencies of bi-allelic inactivation per gene in Signature 8 with either DSBR or Age Related 194 
primary cases revealed no associations (eFigure 7ab). One Signature 8 case bore a germline 195 
missense (rs141465583) of uncertain significance in BRCA1 with somatic loss of the wild type 196 
allele. This variant is unlikely to impair HRR as overexpression of GFP-fused BRCA1 p.P977L 197 
restored the ability of RAD51 to form ionizing radiation-induced foci in U2OS Flp-In cells 198 
depleted of endogenous BRCA1 to a similar extent as wild type GFP-BRCA1 (eFigure 8). Thus, 199 
occult drivers of BRCAness and Signature 8 were either so heterogeneous that each affects few 200 
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cases or not assayed – non-coding, epigenetic, haploinsufficiency of an HRR-pathway gene, 201 
exogenous carcinogens. 202 
 203 
Mutational signatures are linked to predisposition syndromes 204 
Truncating germline mutations of HPCS genes were found in 16 cases in our discovery cohort, 205 
including BRCA1, BRCA2 and PALB2 mutations in 10, MSH2 and MSH6 in 3, ATM in 2 and 206 
CDKN2A in 1. There were 7 HPCS carriers in the replication cohort, including 4 BRCA2, 1 207 
PALB2, 1 ATM and 1 PMS2 (eTable 7). Age at diagnosis differed in discovery but not 208 
replication donors with, versus without, HPCS (pdiscovery=0.0015, preplication=0.32, t-test; eFigure 209 
9). 210 
Most HPCS patients developed tumors driven by processes linked to their 211 
predispositions, demonstrating the importance of recognizing HPCS, including genetic 212 
counseling and germline testing. A minority developed tumors with processes unrelated to their 213 
predisposition. The somatic MMR discovery case had a germline BRCA2 frameshift. Another 214 
discovery donor had a germline MSH6 frameshift, but a tumor that was microsatellite stable and 215 
strongly positive for Signature 17, of unknown etiology. One replication case had a germline 216 
stopgain in PMS2 (not long-range PCR verified) that was microsatellite stable, and two cases 217 
had germline BRCA2 truncations without somatic “second hits” that lacked Signature 3. The 218 
latter agrees with a mouse model heterozygous for BRCA2 that retained the second, functional 219 
allele in PDAC and was not sensitive to mitomycin C and PARP1 inhibitors47. 220 
Nine discovery and seven replication cases had bi-allelic events in ATM. Only one bore 221 
Signature 3, the replication germline ATM carrier who lacked inactivation of another canonical 222 
HRR gene (eFigure 10). 223 
 224 
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Integration of mutational signatures with gene expression 225 
We performed RNASeq on 76 discovery tumors. Our replication cohort had array expression 226 
data for 91 cases. We classified these by Collisson et al.19, Moffitt et al.20 and Bailey et al.21 227 
methodologies. As with other cancers, including melanoma24 and colorectal cancer48, mutational 228 
and transcriptional subtypes did not overlap (eFigure 11). Survival analyses trended towards 229 
worse prognosis in the Moffitt basal subtype (eFigure 12). 230 
We used gene sets23 representative of 16 categories of immune function to characterize 231 
local immune activity. Adaptive immunity and co-inhibition genes were more highly expressed 232 
in DSBR and MMR cases (Figure 4a; eFigure 13a). Cytolytic activity of infiltrating CD8+ T-233 
lymphocytes, measured by the geometric mean of GZMA and PRF1 expression, and co-234 
regulatory molecules, namely CTLA-4, PD-L1, PD-L2 and IDO-1, were increased in DSBR and 235 
MMR relative to Age Related cases (eFigure 14), reminiscent of expression patterns in 236 
melanoma responsive to checkpoint blockade49. Clustering of cases by differential expression of 237 
the genes in these sets23 identified most DSBR (discovery 6 of 6 DSBR, replication 5 of 8) and 238 
all MMR cases as “immunogenic” (eFigure 15-16). The DSBR primary and metastasis pair both 239 
had high cytolytic activity, implying anti-tumor responses are driven intrinsically. 240 
To relate signatures to elevated cytolytic activity, we enumerated tumor neoantigens in 241 
discovery and replication cases. These paralleled SNV counts (rdiscovery=0.98, pdiscovery<3x10-16; 242 
rreplication=0.85, preplication<3x10-16; Pearson’s) (Figure 4b; eFigure 13b) and were elevated in 243 
DSBR and MMR cases (pdiscovery=1.8x10-7; preplication=2.9x10-5; DSBR vs. Age Related; 244 
Wilcoxon) (eFigure 17). The number of neoantigens per SNV did not differ by subtype, implying 245 
no signature was inherently “immunogenic”. Neither neoantigen nor SNV counts were 246 
associated with OS (eFigure 18). We found no other drivers of anti-tumor immunity, including 247 
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incorporation of exogenous viruses, expression of endogenous retroviruses or of cancer testes 248 
antigens. 249 
Equal frequencies of bi-allelic mutations in genes in the DSBR and Age Related cases 250 
(Figure 3) imply that neither tumor suppressor, nor HLA Class 1, nor extrinsic apoptosis gene 251 
inactivation are immune resistance strategies in PDAC. 252 
Cytolytic activity, CD8A and PD-L1 expression strongly correlated with CD8 and PD-L1 253 
immunohistochemistry on a tumor microarray of 33 separate PDAC cases, validating our 254 
RNAseq (Figure 5; p-values in legend). Histology from 81 discovery cases showed no difference 255 
in the degree of peri- and intra-tumoral inflammation across signature classes, implying 256 
microscopy alone cannot accurately measure local anti-tumor immunity (eFigure 19). 257 
 258 
Prognostic and predictive value of mutational signatures 259 
Signature groups were neither prognostic nor associated with tumor grade and stage (eFigure 20-260 
21). Favorable outcomes are anecdotally reported for MMR deficient PDAC50-52. The four 261 
discovery MMR patients had median OS of 1281 days (Q1:Q3 1248-1457 days) compared with 262 
461 (254-1165) for Age-Related cases. The stage IV MMR case is alive 24 months from 263 
diagnosis, responding to immunotherapy. In contrast, the 6 MMR immunodeficient ESPAC 264 
cases had worse survival than immunointact cases (p=0.03, log-rank test; eFigure 22). Rarity of 265 
MMR deficiency precludes definitive conclusions. 266 
Roughly 1 in 10 cases in both cohorts have the DSBR signature. Since HRR deficient 267 
PDAC18, breast42 and ovarian41 cancers may be sensitive to platinum-based therapy, we 268 
compared outcomes in 18 cases treated with either cisplatin or oxaliplatin (eTable 8; eWorksheet 269 
1). In the palliative setting, median PFS was not significantly longer in DSBR than Age Related 270 
cases (181.5 vs. 107 days) (eFigure 23). Platinum responders were observed in both groups, 271 
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suggesting platinum-based therapy may also benefit non-DSBR cases. Sample size limitations 272 
preclude determining whether susceptibility varies with proportion of DSBR. 273 
 274 
DISCUSSION 275 
Mutational signatures in WGS defined four major PDAC classes, namely Age Related, DSBR, 276 
MMR and Signature 8. These were verified, replicated in independent cohorts, associated with 277 
predisposition syndromes and propagated from primary to metastatic lesions. PDAC bearing 278 
DSBR and MMR signatures have elevated local anti-tumor immunity, driven by high levels of 279 
tumor neoantigens and evaded by expression of regulatory genes. This has implications for 280 
personalized management of PDAC. 281 
Approximately 10% of PDAC is categorized as DSBR. Slightly more than half of these 282 
have bi-allelic inactivation of HRR genes; the rest are occult. The latter have lower numbers of 283 
large and small deletions greater than three base pairs relative to DSBR cases with known causal 284 
variants. These BRCAness tumors may have milder HRR deficiency or may represent a novel 285 
process that generates DSBR-like nucleotide substitutions but is distinct from classical HRR 286 
deficiency at a SV level. We might not expect platinum- or PARP inhibitor-based therapies 287 
directed at HRR deficiencies to be as effective in the BRCAness group, nor perhaps in the 288 
somatic DSBR cases that have a lower proportion of Signature 3 attributed SNVs. Similarly, 289 
ovarian cancers with BRCA1 promoter hypermethylation are less sensitive to chemotherapy than 290 
those with BRCA1 mutations53,54, despite both being HRR deficient. This may explain why 291 
exceptional responses to platinum-based chemotherapy are not seen in 10% of PDAC patients in 292 
clinical trials. Our failure to retrospectively detect significant improvement in PFS in a palliative 293 
setting in DSBR cases is also consistent with heterogeneous mechanisms of HRR deficiency and 294 
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secondary platinum resistance. Biomarker-driven prospective trials of PARP inhibitors55 and 295 
platinum-based therapies should clarify this controversy. 296 
Though BRCAness genomes do not appear to be driven by one or few genes, multiple 297 
lines of evidence support the distinction of these cases. At the nucleotide level, the analogous 298 
mutational processes acting in germline, somatic and occult DSBR cases give rise to tumor-299 
specific neoantigens that in turn drive anti-tumor cytolytic activity, a prerequisite to successful 300 
immunotherapy23. A recent study found that metastatic melanoma responding to anti-PD-1 301 
therapy are enriched for mutations in BRCA256. The rate of neoantigen formation per SNV was 302 
equal across signature types, implying that increased mutation rate alone may predict checkpoint 303 
inhibitor response, as shown in colorectal cancer27, and platinum-based chemotherapy response, 304 
as shown in ovarian cancer57. While it has been hypothesized that sequestration protects PDAC 305 
cells from adaptive immunity58-60, our data suggest that resistance occurs through increased 306 
expression of PD-1, CTLA-4 and IDO-1. The potential for immunotherapy in PDAC has 307 
recently been demonstrated in a mouse model that recapitulates its fibrotic stroma using T cells 308 
engineered to recognize PDAC-specific antigen61. The progressive dysfunction of these T cells 309 
in vivo is compatible with our RNA expression findings, implying a role for immune checkpoint 310 
inhibition. Also, high expression of IDO-1 in both DSBR and MMR cases argues for trials of 311 
IDO-1 inhibitors in PDAC, as in other cancers62,63. Current limited success of immunotherapy in 312 
PDAC7,8 may be because only a minority of cases have significant local anti-tumor activity. 313 
Nonetheless, our data do not prove responsiveness to immunotherapies in subtypes of PDAC. 314 
Other important factors, such as host immunocompetence and tumor microenvironment, must be 315 
better understood to facilitate use of immunotherapeutics in clinical settings. 316 
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The nature of our cDNA-based RNA capture did not allow assessment of expression of 317 
all endogenous retroviruses or cancer testes antigens, nor quantification of tumor cellularity from 318 
RNASeq. Tumor cellularity estimates of the same fresh tissue from sections used for WGS were 319 
not significantly different between subtypes (eFigure 3). Our outcome analyses are limited by the 320 
retrospective nature of this work, including non-randomized patient treatment selection and 321 
possible confounding factors not balanced between subtypes. Also, bi-allelic inactivation of 322 
other genes important to both DNA damage response and PDAC predisposition, such as ATM64, 323 
were not associated with signatures, implying that either our whole genome sample size was too 324 
small to detect all mutational processes or that the contribution of mutations produced by some 325 
processes were too few to be detected30. Nonetheless, that genomic and transcriptomic data 326 
generated separately with different platforms agree in all aspects validates our findings. 327 
Ours and other sequencing efforts have focused on resectable PDAC, constituting a fifth 328 
of cases. Improving outcomes for the majority of patients with metastatic disease is sorely 329 
needed. Our analysis provides a framework for integrating genomics and transcriptomics to 330 
suggest translatable differences between tumor subtypes. We are now applying this to whole 331 
genome and transcriptome sequences from tumor biopsies to understand resistance to 332 
conventional treatment and to select second-line strategies for patients with advanced disease 333 
within the context of a prospective clinical trial (NCT- 02750657). 334 
 335 
336 
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Figure and Table Captions 337 
Figure 1: 338 
(A) Barplot of proportion of seven merged signatures in each of the 160 discovery tumors, sorted 339 
by hierarchical clustering (dendogram at bottom), showing germline (dark blue), somatic 340 
(mauve) and occult (clear) DSBR etiologies and heatmaps for total number of single nucleotide 341 
variants (SNVs), total number of neoantigens, total number of indels, total number of short 342 
deletions greater than 3 base pairs, total number of structural deletions, and transcriptional 343 
subtypes (Moffitt Tumor class, Collisson class and Bailey class) in cases for which RNASeq is 344 
available for the tumor; 345 
(B) Barplots of proportion of 7 merged signatures in paired primary tumors and metastases from 346 
4 cases. 347 
 348 
Figure 2: 349 
Boxplots of proportion of SNVs attributed to Signature 3, number of short deletions greater than 350 
3 base pairs in length, number of SVs, and number of large (structural) deletions in the DSBR 351 
subtype divided by etiology – germline (dark blue), BRCAness / occult (clear) or somatic 352 
(mauve) – and in the Age Related subtype (light blue), for amalgamated discovery and 353 
replication cohorts. All values are significantly greater in both DSBR germline and BRCAness / 354 
occult groups relative to the Age Related subtype, p < 0.0002 for each, Wilcoxon test, as marked 355 
by asterisks. 356 
 357 
Figure 3: 358 
Scatterplot of proportions of cases with bi-allelic inactivation of every gene in the DSBR subtype 359 
primary tumors (n=27) versus that in the Age Related subtype primary tumors (n=169) for the 360 
amalgamated discovery and replication cohorts. Driver genes include CDKN2A, SMAD4, TP53. 361 
FDR = false discovery rate 362 
 363 
Figure 4: 364 
(A) Heatmap of median expression of gene sets representative of categories of immune function 365 
by signature group for discovery cohort cases with tumor cellularities between 20-80%; 366 
(B) Scatterplot of number of neoantigens (y-axis) versus number of somatic SNVs (single 367 
nucleotide variants, x-axis) per tumor, colored by signature-based subtype, for 137 discovery 368 
cohort cases to which we confidently assigned HLA Class 1 genotypes. Regression line from 369 
linear model (y ~ x) is shown in black with areas between confidence bands shaded in grey. 370 
 371 
Figure 5: 372 
(A) PD-L1 and CD8 immunohistochemical expression in representative cancer TMA spots 373 
showing high (left column) and low (right column) expression of PD-L1 (top row) and CD8 374 
counts (bottom row); 375 
(B) Median (dotted lines) and interquartile ranges (shaded regions) of expression of PD-L1, 376 
CD8A and cytolytic activity (left-sided y-axis) and absolute counts of cells with 377 
immunohistochemical staining for CD8 (right-sided y-axis) at each level of PD-L1 378 
immunohistochemical staining (0-3, see Methods). CD8 staining cell counts and CD8A 379 
expression were strongly correlated (p = 7.1x10-7, R 0.744, Pearson’s correlation). PD-L1 and 380 
cytolytic activity expression were significantly higher across PD-L1 staining levels (pPD-L1 = 381 
0.0064, pcytolytic activity = 0.01, PD-L1 0-1 vs 2-3 staining, Wilcoxon test). 382 
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eFigure 1: 386 
Barplot of proportion of seven merged signatures in each of the 95 replication tumors, sorted by 387 
hierarchical clustering (dendrogram at bottom), showing germline (blue), somatic (mauve) and 388 
occult (clear) DSBR etiologies and heatmaps for total number of SNVs, total number of 389 
neoantigens, total number of indels, total number of short deletions greater than 3 base pairs, 390 
total number of structural deletions, and transcriptional subtypes (Moffitt Tumor class, Collisson 391 
class and Bailey class) in cases for which expression microarray data are available for the tumor. 392 
 393 
eFigure 2: 394 
Hierarchical clustering of (A) 160 discovery and (B) 95 replication cohort samples according to 395 
proportion (see Figure 1a and eFigure 1) of seven merged signatures in each tumor. Dark green = 396 
MMR, dark blue = DSBR, gold = Signature 8, light green = APOBEC, pink = Signature 17, light 397 
blue = Age Related 398 
 399 
eFigure 3: 400 
Boxplots of (A) & (C) cellularity and (B) & (D) mean tumor coverage by signature-based 401 
subtype for (A) & (B) discovery and (C) & (D) replication cohorts 402 
 403 
eFigure 4: 404 
Scatterplots of age at surgery versus either (A) & (E) total number of somatic SNVs, (B) & (F) 405 
number of SNVs attributed to Age Related signatures, (C) & (G) number of SNVs attributed to 406 
Signature 1, (D) & (H) number of SNVs attributed to Signature 5 in (A-D) discovery and (E-H) 407 
replication cohorts. Regression lines from linear models (y ~ x) are shown in solid black with 408 
areas between confidence bands shaded in grey 409 
 410 
eFigure 5: 411 
Boxplots of number of (A) & (G) SVs, (B) & (H) structural (large) deletions, (C) & (I) 412 
inversions, (D) & (J) duplications, (E) & (K) transversions, and (F) & (L) short deletions >3 base 413 
pairs in tumors of each signature-based subtypes for (A-F) discovery and (G-L) replication 414 
cohorts. P-values from comparison of numbers of each somatic variant class in DSBR vs Age 415 
Related subtypes by Wilcoxon test 416 
 417 
eFigure 6: 418 
Smoking status in Age Related (‘signature.1.5’) and Signature 8 (‘signature.8’) in (A) discovery 419 
and (B) replication cohorts.  420 
 421 
eFigure 7: 422 
Scatterplot of frequency of bi-allelic inactivation of every gene in (A) the Signature 8 subtype 423 
primary tumors (n=36) versus that in the Age Related subtype primary tumors (n=169) and in 424 
(B) the Signature 3 subtype primary tumors (n=27) versus that in the Signature 8 subtype 425 
primary tumors (n=36) for the amalgamated discovery and replication cohorts. Driver genes 426 
include CDKN2A, SMAD4, TP53. FDR = false discovery rate 427 
 428 
eFigure 8: 429 
RAD51 assay performed on BRCA1 p.P977L (rs141465583) germline variant of uncertain 430 
significance demonstrates ability of variant allele to restore irradiation-induced foci. 431 
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 432 
eFigure 9: 433 
Boxplots of (A) age at surgery in discovery cohort, (B) age at diagnosis in replication cohort, and 434 
(C) the amalgamated cohorts for those cases with and without pathogenic germline variants in 435 
HPCSs genes. P values for comparison of ages in Hereditary Pancreas Cancer Syndrome (HPCS) 436 
carriers vs non-HPCS carriers are by t-test. 437 
 438 
eFigure 10: 439 
Stripcharts of proportion of SNV’s attributed to each merged signature in cases with bi-allelic 440 
inactivation vs monoallelic inactivation and wild type ATM for the amalgamated discovery and 441 
replication cohorts. 442 
 443 
eFigure 11: 444 
Proportions of (A,C,E) Moffit tumor and (B,D,F) Collisson transcriptional-based subtypes 445 
composed of each signature-based subtype for (A-B) discovery, (C-D) replication and (E-F) 446 
combined cohorts. 447 
 448 
eFigure 12: 449 
Overall survival curves for (A,D) Moffitt tumor, (B,E) Collisson and (C,F) Bailey 450 
transcriptional-based subtypes in (A-B) discovery and (C-D) replication cohorts. 451 
 452 
eFigure 13: 453 
(A) Heatmap of median expression of gene sets representative of categories of immune function 454 
by signature group for replication cohort cases with tumor cellularities between 20-80%; 455 
(B) Scatterplots of number of neoantigens (y-axis) versus number of somatic SNVs (single 456 
nucleotide variants, x-axis) per tumor, colored by signature-based subtype, for 87 replication 457 
cohort cases to which we confidently assigned HLA Class 1 genotypes. Regression line from 458 
linear model (y ~ x) is shown in black with areas between confidence bands shaded in grey. 459 
 460 
eFigure 14: 461 
Boxplots of expression of cytolytic activity, CTLA-4, PD-L1, PD-L2 and IDO-1 in signature-462 
based subtypes in discovery (top row) and replication (bottom row) cohort cases with tumor 463 
cellularities between 20-80%. The differences in expression between AR (Age Related) and 464 
either DSBR or MMR are calculated by Wilcoxon test; FPKM = Fragments Per Kilobase of 465 
transcript per Million mapped reads. 466 
 467 
eFigure 15: 468 
Heatmap of expression of 113 genes representative of categories of immune function in 469 
discovery RNASeq cases with tumor cellularities between 20-80%. Hierarchical clustering 470 
shows increased immune activity in all discovery DSBR (6 of 6) and MMR (2 of 2) cases. 471 
 472 
eFigure 16: 473 
Heatmap of expression of 113 genes representative of categories of immune function in 474 
replication microarray expression cases with tumor cellularities between 20-80%. Hierarchical 475 
clustering shows increased immune activity in 5 of 8 DSBR. 476 
 477 
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eFigure 17: 478 
Boxplots of (A,D) number of neoantigens, (B,E) number of somatic single nucleotide variants 479 
(SNV), (C,F) number of neoantigens per SNV in tumors of each signature-based subtypes for 480 
(A-C) discovery and (D-F) replication cohorts. P values calculated by Wilcoxon test. 481 
 482 
eFigure 18: 483 
Overall survival curves with stratification by standard deviation of (A,D) somatic single 484 
nucleotide variants (SNV), (B,E) somatic insertion and deletion variants and (C,F) neoantigen 485 
load (A-C) discovery and (D-F) replication cohorts. 486 
 487 
eFigure 19: 488 
Proportions of tumors divided by (A,C) presence or absence and (B,D) degree of (A-B) intra- 489 
and (C-D) peri-tumoral inflammation composed of each signature-based subtype for the 490 
discovery cohorts cases with haematoxylin and eosin stained slides available (n = 81). 491 
 492 
eFigure 20: 493 
Overall survival curves for signature-based subtypes in (A) discovery and (B) replication 494 
cohorts. 495 
 496 
eFigure 21: 497 
Proportions of tumors divided by (A) histologic grade, (B) T stage, (C) N stage, (D) M stage 498 
composed of each signature-based subtype for (A-D) discovery and (E-H) replication cohorts. 499 
 500 
eFigure 22: 501 
Overall survival curve for ESPAC cohort according to mismatch repair protein 502 
immunohistochemistry (IHC) deficiency. 503 
 504 
eFigure 23: 505 
Progression free survival with stratification by Signature 3 (DSBR) vs Signatures 1+5 (Age 506 
Related) for (A) all cases that received platinum-based palliative chemotherapy and (B) all cases 507 
that responded to platinum-based palliative chemotherapy. P values by univariable Cox 508 
proportional hazard models. 509 
 510 
 511 
  512 
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eTable 1: 513 
Summary of clinical and pathologic data for discovery and replication cohorts with appropriate 514 
statistical comparisons between the two groups. 515 
 516 
eTable 2: 517 
Summary of immunohistochemistry of 4 MMR proteins and PCR-based microsatellite instability 518 
testing for discovery cohort. Acronyms: MSS = microsatellite stable; MSI = microsatellite 519 
instability; NA = not available 520 
 521 
eTable 3: 522 
Summary of germline and somatic mutations in hereditary pancreatic cancer syndrome (HPCS) 523 
genes in cases whose tumors had mismatch repair deficiency in the discovery cohort. 524 
 525 
eTable 4: 526 
Number of cases per signature-based subtype per cohort and derived population-level estimates. 527 
 528 
eTable 5: 529 
Summary of clinical and pathologic data, including palliative chemotherapy regimens, received 530 
by cases with paired primaries and tumours (for signatures, see Figure 1B). 531 
 532 
eTable 6a,b: 533 
Summary of germline and somatic mutations in BRCA1, BRCA2 and PALB2 in cases whose 534 
tumors have evidence of double strand break repair deficiency in discovery and replication 535 
cohorts. Acronym: LOH = loss of heterozygosity of the wild type allele of the affected gene 536 
 537 
eTable 7a,b: 538 
Summary of pathogenic germline variants in hereditary pancreatic cancer syndrome (HPCS) 539 
genes in discovery and replication cohorts. 540 
 541 
eTable 8: 542 
Summary of cases that received platinum-based palliative chemotherapy in the discovery cohort; 543 
see Supplement One for statistical methodologies. 544 
 545 
eWorksheet 1: 546 
Treatment details of cases that received platinum-based palliative chemotherapy in the discovery 547 
cohort; see Supplement One for further details. 548 
 549 
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